AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for NYSE:ABBV*
62.43
-0.55 (-0.87%)
Jan 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 62.35 - 63.66
52 week 45.50 - 70.76
Open 63.66
Vol / Avg. 6.88M/7.88M
Mkt cap 99.48B
P/E 27.06
Div/yield 0.49/3.14
EPS 2.31
Shares 1.59B
Beta     -
Inst. own 88%
Jan 30, 2015
Q4 2014 AbbVie Inc Earnings Release - 9:30AM EST - Add to calendar
Jan 30, 2015
Q4 2014 AbbVie Inc Earnings Call - 9:00AM EST - Add to calendar
Jan 14, 2015
AbbVie Inc at JPMorgan Healthcare Conference
Jan 6, 2015
AbbVie Inc at Goldman Sachs CEOs Unscripted Healthcare Conference - Webcast
Nov 20, 2014
AbbVie Inc at Jefferies Global Healthcare Conference - London - Webcast
Nov 13, 2014
AbbVie Inc at Credit Suisse Healthcare Conference
Oct 31, 2014
Q3 2014 AbbVie Inc Earnings Release
Oct 31, 2014
Q3 2014 AbbVie Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 10.08% 21.97%
Operating margin 19.13% 30.14%
EBITD margin - 36.59%
Return on average assets 7.06% 14.69%
Return on average equity 41.16% 105.11%
Employees 25,000 -
CDP Score - -

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company�s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn�s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson�s disease, and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions, such as low testosterone. AbbVie's portfolio of products includes HUMIRA, Synthroid, AndroGel, Creon, Kaletra, Norvir, Lupron, Niaspan, TriCor, TRILIPIX, Synagis, Duodopa, Duopa, Zemplar and Sevoflurane AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across medical specialties as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women�s health. It markets medicines in approximately 170 countries.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
William J. Chase Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President - Business Development, External Affairs, General Counsel
Age: 50
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Roxanne S. Austin Independent Director
Age: 53
Bio & Compensation  - Reuters